Ação do VM-26 em Casos de Doença de Hodgkin Estádios III e IV

Authors

  • Sebastião Cabral Filho Médico Assistente. Serviço de Oncologia Clínica da Santa Casa de Misericórdia. Belo Horizonte (MG), Brasil
  • José Ramos Júnior Diretor. Departamento de Medicina. Hospital A.C. Camargo. Fundação Antonio Prudente. São Paulo (SP), Brasil
  • Eloy Parisi Chefe. Serviço de Clínica Médica do Hospital A.C. Camargo. Fundação Antonio Prudente. São Paulo (SP), Brasil
  • Normando de Bellis Chefe. Serviço de Clínica Médica do Hospital A.C. Camargo. Fundação Antonio Prudente. São Paulo (SP), Brasil
  • Itiel Bubman Médicos titulares. Serviço de Clínica Médica do Hospital A.C. Camargo. Fundação Antonio Prudente. São Paulo (SP), Brasil
  • Alfonso Jimenes Mendes Médicos titulares. Serviço de Clínica Médica do Hospital A.C. Camargo. Fundação Antonio Prudente. São Paulo (SP), Brasil

DOI:

https://doi.org/10.32635/2176-9745.RBC.1976v26n5.3811

Keywords:

Hodgkin Disease/therapy, Teniposide/therapeutic use, Teniposide/toxicity

Abstract

The authors studied the Efficiency of a new podophyllotoxin derivative, in 10 patients with Hodgkin's disease stage III and IV. They obtained 60% of objective responses but no one case of complete remission. Appart from 2 cases of alopecia of median intensity, there were not any side effects with the treatment employed. The authors also found that the doses given were low, proposing further studies with higher doses and new schemes, including the association of VM-26 to other drugs for a better use of the potenciality of this new compound. Finally they concluded that VM-26 could be part of the antiblastic therapeutic arsenal considering its efficiency and its capacity of transposing the hematoencefalic barrier.

Downloads

Download data is not yet available.

References

BURCHENAL, J.H., CARTER, S. K.: — New câncer chemotherapeutic agents", Cancer 6: 1639, 1972. DOI: https://doi.org/10.1002/1097-0142(197212)30:6<1639::AID-CNCR2820300633>3.0.CO;2-4

DE VITA, V.T. Jr., SERPICK, A. and CARBONE, P.P.: Combination of chemotherapy in the treatment of advanced Hodgkin's disease, Ann. lntern. Med. 73: 881, 1970.

European Organization for Research and the Treatment of Cancer: Clinical screening of 4'demethylepy-podophyllotoxin-B-thenylidene glucoside (VM-26) in malignant lymphomas and solid tumors. Brit. Med. J. 2:744, 1972.

GLATSTEIN, E.; TRUEBLOOD, H.W., ENRIGHT, L.P., ROSENBERG, S.A. and KAPLAN. H.S.: Surgical staging of abdominal invoivement in unseíected patients with Hodgkin's disease. Radiology 97:425, 1970. DOI: https://doi.org/10.1148/97.2.425

GRADWOHL, P.R. and STAHELIN, H.: Effect of VM-26, a podophyHotoxin glucosis derivative on the uptake of 3H-thymidine, 3H-uridine, and 3H-leucine by P-815 mastocytoma celis in vitro. International Cancer Congress Abstracts; Houston, Texas, page 398, 1970.

JUNGI, W. E.; SENN, H.J.: Clinical study of the neva podophyllotoxin derivative, 4JdemethyIeppodophyIlotox in-9-(4,6-0-ethyl idene-B-D-glucopyranoside) (NCS-141540; VP 16-213), in solid tumors in man. Cancer Chem Rep., 59: 737. 1975.

MATHÉ, G.; SCHWARZENBERG, L.: Two epipodophyllotoxin derivatives, VM-26 and VP 16213, in the treatment of leu kemias, hematosarcoma, and Iymphomas. Cancer :985, 1974. DOI: https://doi.org/10.1002/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO;2-U

MUGGIA, EM.: Phase 1 study of 4'demethylepipodophy11otoxin-13-D-theny1idene glucoside (PTG, NSC 122819). Proc. Amer., Ass, Cancer Res. 11:58, 1970.

MUGGIA, F.M.,s SELAWRY, OS., and, HANSEN. H.H.: Clinical Studies with a new podophyllotoxin derivative, 4'demethylepipodophyllotox in- B-D-the-nylidene glucoside. Cancer Chemother Rep. 55: 575, 1971.

RIVERA, G.; AVERY, T.; PRATT, G.: 4'demethylepipodophy11otoxin9 -(4,6-02-theny1idene-13-D-glucopyranoside) (NSC-122819: VM-26) and 4'demethyIepipodophyI1otoxin-9 )4,6-0-ethylidene-13-D-glucopyranoside) (NSC-141540: VP-16213) in childhood cancer: Preliminary Observations. Cancer Chem Rep. 59:743,1975.

ROSENBERG, S. MD.: "A critique of the value of laparatomy and splenectomy and the evaluation of pacients with Hodgkin's disease, Cancer Res, 31:1737,1971.

ROSENBERG, S.A. and KAPLAN, H.S.: "Hodgkin's disease and other malignant lymphomas". Calif. Med. 11.23, 1970.

SKLANSKY, B.D., MANN-KAPLAN, R.S.: 4'demethylepipodophyllotoxin-B-D-thenylidene- glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer2:460, 1974. DOI: https://doi.org/10.1002/1097-0142(197402)33:2<460::AID-CNCR2820330222>3.0.CO;2-5

STAHELIN, H.: 4'Demethylepipodophyllotoxin-thenyiidene-glucose (VM-26) a podophy!lotoxin compound with neva mechanism of action. Europ. J. Cancer 6: 301, 1970. DOI: https://doi.org/10.1016/0014-2964(70)90095-2

STAHELIN, H.: VM-26 a neva podophyllotoxin glucoside derivative with anti-L-1 210 activity. Proc. Amer. Cfncer-Res. 10:68, 1969.

TREMPE, G., SYKES, M.,1 YOUNG, C., and KRAKOFF, 1: Phase 1 trial of the podophyllotoxin derivative VM-26. Proc. Amer. Ass. Cancer Res. ,11:79, 1970.

ULTMANN, E.; JOHN, M.D. Moran, M. and Edgard, MD: "Clinical course and complication in Hodgkin's disease. Arch. lntern. Med. 131:332, 1973. DOI: https://doi.org/10.1001/archinte.1973.00320090022003

Downloads

Published

2023-08-15

How to Cite

1.
Cabral Filho S, Ramos Júnior J, Parisi E, Bellis N de, Bubman I, Mendes AJ. Ação do VM-26 em Casos de Doença de Hodgkin Estádios III e IV. Rev. Bras. Cancerol. [Internet]. 2023 Aug. 15 [cited 2024 Jul. 22];26(5):5-13. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/3811

Issue

Vol. 26 No. 5 (1976): Sept./Oct.

Section

ORIGINAL ARTICLE

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

1 2 > >>